Table 4. Primary and Secondary Outcomes .
| RAAS | Control | P | |
| % Survival > 1 year | 100 (71/71) | 100 (98/98) | 1.000 |
| % Survival > 2 year | 95 (38/40) | 79 (48/61) | 0.042 |
| Periprocedural major vascular | 7 (5) | 5 (5) | 0.744 |
| Periprocedural minor vascular | 7 (5) | 7 (7) | 1.000 |
| Post-TAVR PPM implantation | 11 (8) | 10 (10) | 1.000 |
| Periprocedural increase in serum creatinine >1.5x baseline | 3 (2) | 7 (7) | 0.306 |
| In Hospital | |||
| MI | 0 (0) | 1 (1) | 1.000 |
| Stroke/TIA | 1 (1) | 0 (0) | 0.420 |
| HF exacerbation | 21 (15) | 20 (20) | 1.000 |
| All-cause mortality | 0 (0) | 0 (0) | 1.000 |
| Discharge to 30 days | |||
| MACCE | 18 (13) | 21 (21) | 0.699 |
| Myocardial Infraction | 3 (2) | 1 (1) | 0.573 |
| Stroke/TIA | 0 (0) | 0 (0) | 1.000 |
| HF exacerbation | 17 (12) | 20 (20) | 0.691 |
| Rehospitalization for any reason | 18 (13) | 21 (21) | 0.699 |
| All-cause Mortality | 0 (0) | 0 (0) | 1.000 |
| 30 days- 6 months | |||
| MACCE | 18 (13) | 23 (23) | 0.452 |
| Myocardial Infraction | 0 (0) | 2 (2) | 0.510 |
| Stroke/TIA | 3 (2) | 1 (1) | 0.573 |
| HF exacerbation | 8 (6) | 21 (21) | 0.032 |
| Rehospitalization for any reason | 17 (12) | 23 (23) | 0.340 |
| All-cause mortality | 0 (0) | 0 (0) | 1.000 |
| 6 months-1 year | |||
| MACCE | 21 (15) | 33 (32) | 0.118 |
| Myocardial Infraction | 3 (2) | 2 (2) | 1.000 |
| Stroke/TIA | 1 (1) | 2 (2) | 1.000 |
| HF exacerbation | 15 (11) | 23 (23) | 0.245 |
| Rehospitalization for any reason | 20 (14) | 32 (31) | 0.112 |
| All-cause Mortality | 0 (0) | 0 (0) | 1.000 |
Values are % (n).
MACCE = major adverse cardiovascular and cerebrovascular events, defined as death from any cause, myocardial infarction, rehospitalization, and stroke.